JP2014510793A - 集団のサブセットにおける非小細胞肺癌の治療での使用のためのモテサニブ、タキサン、および白金含有抗癌剤の組み合わせ - Google Patents

集団のサブセットにおける非小細胞肺癌の治療での使用のためのモテサニブ、タキサン、および白金含有抗癌剤の組み合わせ Download PDF

Info

Publication number
JP2014510793A
JP2014510793A JP2014505293A JP2014505293A JP2014510793A JP 2014510793 A JP2014510793 A JP 2014510793A JP 2014505293 A JP2014505293 A JP 2014505293A JP 2014505293 A JP2014505293 A JP 2014505293A JP 2014510793 A JP2014510793 A JP 2014510793A
Authority
JP
Japan
Prior art keywords
motesanib
use according
asian
lung cancer
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014505293A
Other languages
English (en)
Japanese (ja)
Inventor
ヘイ，ヨン−ジアン
ヤオ，ビン
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2014510793A publication Critical patent/JP2014510793A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2014505293A 2011-04-13 2012-04-12 集団のサブセットにおける非小細胞肺癌の治療での使用のためのモテサニブ、タキサン、および白金含有抗癌剤の組み合わせ Pending JP2014510793A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161475163P 2011-04-13 2011-04-13
US61/475,163 2011-04-13
PCT/US2012/033376 WO2012142325A1 (en) 2011-04-13 2012-04-12 Combination of motesanib, a taxane and a platinum-containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset

Publications (1)

Publication Number Publication Date
JP2014510793A true JP2014510793A (ja) 2014-05-01

Family

ID=46018098

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014505293A Pending JP2014510793A (ja) 2011-04-13 2012-04-12 集団のサブセットにおける非小細胞肺癌の治療での使用のためのモテサニブ、タキサン、および白金含有抗癌剤の組み合わせ

Country Status (7)

Country Link
JP (1) JP2014510793A (ko)
KR (1) KR20140022876A (ko)
CN (1) CN103764139A (ko)
AU (1) AU2012242773A1 (ko)
SG (1) SG194453A1 (ko)
TW (1) TW201304777A (ko)
WO (1) WO2012142325A1 (ko)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6016000413; 'Ａ　ｐｈａｓｅ　ＩＩ，　ｍｕｌｔｉｃｅｎｔｅｒ，　ｏｐｅｎ-ｌａｂｅｌ　ｒａｎｄｏｍｉｚｅｄ　ｓｔｕｄｙ　ｏｆ　ｍｏｔｅｓａｎｉｂ　ｏｒ　ｂｅｖａｃｉｚｕｍａｂ　ｉｎ　ｃｏｍｂｉｎａｔｉｏｎ　ｗｉｔｈ' Ａｎｎ　Ｏｎｃｏｌ ｖｏｌ．２２，ｎｏ．９, 20110214, ｖｏｌ．２０５７-６７ *

Also Published As

Publication number Publication date
SG194453A1 (en) 2013-12-30
CN103764139A (zh) 2014-04-30
WO2012142325A1 (en) 2012-10-18
KR20140022876A (ko) 2014-02-25
TW201304777A (zh) 2013-02-01
AU2012242773A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
EP1915151B1 (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors
US20090030005A1 (en) Combinations for the treatment of cancer
EP1358184B1 (en) N-(3,3-Dimethylindolin-6-yl){2-[(4-pyridylmethyl)amino}(3-pyridyl)}carboxamide and pharmaceutical compositions thereof.
US20140243339A1 (en) Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
WO2013074518A1 (en) Modulating certain tyrosine kinases
US8648199B2 (en) Process for making a solid-state form of AMG 706
JP2014055143A (ja) Ａｍｇ７０６の水和物形態
US20150336915A1 (en) Structures of proteasome inhibitors and methods for synthesizing and use thereof
JP2014510793A (ja) 集団のサブセットにおける非小細胞肺癌の治療での使用のためのモテサニブ、タキサン、および白金含有抗癌剤の組み合わせ
ES2367872T3 (es) Combinaciones para el tratamiento de cáncer que comprenden un anticuerpo anti-egfr e inhibidores de vegfr.
WO2020223235A1 (en) Mini-tablet dosage forms of ponatinib
ES2367286T3 (es) Forma en estado sólido de amg 706 y composiciones farmacéuticas de la misma.

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160413

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160920